Impact BioMedical

IBO

Biotechnology · Healthcare

Exchange

New York Stock Exchange American

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Data as of Aug 9, 2026 · filings through Mar 31, 2026

Impact BioMedical Inc. is a small biotechnology company focused on developing treatments and health products, including antiviral and antimicrobial compounds. Its work centers on proprietary formulations aimed at fighting infections and supporting immune health. The company targets pharmaceutical and consumer health markets, though it remains in early stages of commercialization.

Impact BioMedical generates very little revenue today, relying primarily on research partnerships and licensing arrangements rather than large-scale product sales. It operates mainly in the United States and is a micro-cap company with a market value near zero, reflecting its pre-revenue status. The deeply negative margins shown in its financials confirm it spends far more than it earns, which is common for early-stage biotech firms. The central risk is whether the company can secure enough funding and partnerships to advance its compounds through development before running out of capital.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+78.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

2.6%ownership

Relatively low insider ownership

Cash Runway

~0 months

$20,000 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Impact BioMedical has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-1225.0%

Thin — -1225.0% gross margin

Operating Margin

-13343.8%

Losing money on operations — -13343.8%

ROCE

-33.9%

Weak — -33.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-98.0%

—

Shrinking sales (-98.0% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-5906.3%

Burning cash (-5906.3%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial